Dr. Russell Jenkins obtained his Bachelor’s degree in biology at the University of Virginia in 2002 and his MD/PhD at the Medical University of South Carolina in 2012. He completed his internship and residency in Internal Medicine at Massachusetts General Hospital in 2014 and his clinical oncology training in the Dana-Farber/Harvard Cancer Center in 2017. He conducted his post-doctoral research in Dr. David Barbie’s lab at the Dana-Farber Cancer Institute where he developed a novel platform to study ex vivo response to PD1- blockade using organotypic tumor spheroids. In 2018, he joined the faculty at the MGH Cancer Center in the Center for Melanoma and Center for Cancer Research. Dr. Jenkins was the inaugural Termeer Early Career Investigator in Systems Pharmacology and a member of the Laboratory for Systems Pharmacology at Harvard Medical School. He is also an Associate Member of the Cancer Program at the Broad Institute of MIT and Harvard. The Jenkins laboratory studies mechanisms of response and resistance to PD-1 blockade with a focus on developing rational combination therapies to overcome resistance to cancer immunotherapy.
Investigator, Center for Cancer Research, MGH;
Assistant Professor of Medicine, HMS
Join our email list to recieve exclusive offers